Opioid Use Disorder (OUD) Market Size 2020 | North America, Europe & Asia Pacific Regions to Dominate the Global Industry

Opioid Use Disorder (OUD) Market Size 2020 | North America, Europe & Asia Pacific Regions to Dominate the Global Industry


The global opioid use disorder (OUD) market size is projected to reach USD 4.50 billion by 2026, exhibiting a CAGR of 10.8% during the forecast period. Increasing addiction to opioids across the globe will be the central force driving the growth of this market, shares Fortune Business Insights™ in its recent report, titled “Opioid Use Disorder (OUD) Market Size, Share & Industry Analysis, By Drug Class (Buprenorphine, Methadone, and Naltrexone), By Route of Administration (Oral, and Parenteral), By Distribution Channel (Hospital Pharmacies, Retails Pharmacies & Stores, and Online Pharmacies), and Regional Forecast, 2019-2026”. The US National Institutes of Health (NIH) estimates that approximately 16 million people around the world are suffering from opioid use disorder (OUD). In the US, the situation has worsened in the past few years, with the US government declaring opioid overdose a public health emergency in the country in 2017. As per NIH data, roughly 3 million Americans have OUD and over half a million US citizens are dependent on heroin. The NIH also reports that in 2015 nearly 92 million Americans used prescription opioids. This heightening dependency on opioids in the US and worldwide is likely to set the opioid use disorder market trends in the near future.


Please visit: https://www.fortunebusinessinsights.com/opioid-use-disorder-oud-market-102674

Detailed Table of Content:

 

1.       Introduction

1.1.    Research Scope

1.2.    Market Segmentation

1.3.    Research Methodology

1.4.    Definitions and Assumptions

2.       Executive Summary

3.       Market Dynamics

3.1.    Market Drivers

3.2.    Market Restraints

3.3.    Market Opportunities

4.       Key Insights

4.1.    Pipeline Analysis

4.2.    New Product Launches

4.3.    Statistics of Opioid Use Disorder

4.4.    Industry Developments Such as Mergers, Acquisitions, and Collaborations

5.       Global Opioid Use Disorder (OUD) Market Analysis, Insights and Forecast, 2015-2026

5.1.    Key Findings / Summary

5.2.    Market Analysis, Insights and Forecast – By Drug Class

5.2.1. Buprenorphine

5.2.2. Methadone

5.2.3. Naltrexone

5.3.    Market Analysis, Insights and Forecast – By Route of Administration

5.3.1. Oral

5.3.2. Parenteral

5.4.    Market Analysis, Insights and Forecast – By Distribution Channel

5.4.1. Hospitals Pharmacies

5.4.2. Retail Pharmacies & Stores

5.4.3. Online Pharmacies

5.5.    Market Analysis, Insights and Forecast – By Region

5.5.1. North America

5.5.2. Europe

5.5.3. Asia Pacific

5.5.4. Rest of the World

6.       North America Opioid Use Disorder (OUD) Market Analysis, Insights and Forecast, 2015-2026

6.1.    Key Findings / Summary

6.2.    Market Analysis – By Drug Class

6.2.1. Buprenorphine

6.2.2. Methadone

6.2.3. Naltrexone

6.3.    Market Analysis – By Route of Administration

6.3.1. Oral

6.3.2. Parenteral

6.4.    Market Analysis – By Distribution Channel

6.4.1. Hospitals Pharmacies

6.4.2. Retail Pharmacies & Stores

6.4.3. Online Pharmacies

6.5.    Market Analysis – By Country

6.5.1. U.S.

6.5.2. Canada

7.       Europe Opioid Use Disorder (OUD) Market Analysis, Insights and Forecast, 2015-2026

7.1.    Key Findings / Summary

7.2.    Market Analysis – By Drug Class

7.2.1. Buprenorphine

7.2.2. Methadone

7.2.3. Naltrexone

7.3.    Market Analysis – By Route of Administration

7.3.1. Oral

7.3.2. Parenteral

7.4.    Market Analysis – By Distribution Channel

7.4.1. Hospitals Pharmacies

7.4.2. Retail Pharmacies & Stores

7.4.3. Online Pharmacies

7.5.    Market Analysis – By Country/ sub-region

7.5.1. U.K.

7.5.2. Germany

7.5.3. France

7.5.4. Spain

7.5.5. Italy

7.5.6. Scandinavia

7.5.7. Rest of Europe

8.       Asia Pacific Opioid Use Disorder (OUD) Market Analysis, Insights and Forecast, 2015-2026

8.1.    Key Findings / Summary

8.2.    Market Analysis – By Drug Class

8.2.1. Buprenorphine

8.2.2. Methadone

8.2.3. Naltrexone

8.3.    Market Analysis – By Route of Administration

8.3.1. Oral

8.3.2. Parenteral

8.4.    Market Analysis – By Distribution Channel

8.4.1. Hospitals Pharmacies

8.4.2. Retail Pharmacies & Stores

8.4.3. Online Pharmacies

8.5.    Market Analysis – By Country

8.5.1. Japan

8.5.2. China

8.5.3. India

8.5.4. Australia

8.5.5. Southeast Asia

8.5.6. Rest of Asia Pacific